{
  "ticker": "MDR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975005",
  "id": "02975005",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0922",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mc621h8cx9f1.pdf",
  "summary": "### **MedAdvisor Limited (ASX: MDR) \u2013 Material Information Summary**  \n\n#### **Quarterly Report (Appendix 4C) & Guidance Update**  \n- **Revenue & Margins**:  \n  - **4Q FY25 revenue**: $18.6M (\u219316.6% pcp); **FY25 revenue**: $88.0M (\u219327.9% pcp).  \n  - **Gross margin**: 59.7% (\u21939.8ppt pcp).  \n  - **Operating cash outflow**: $2.0M (vs. $3.6M outflow pcp).  \n\n- **Capital Raising**:  \n  - **$7.7M raised** ($5M placement, $2.7M SPP at $0.10/share).  \n\n- **ANZ Divestment**:  \n  - **Sold for $35M** (headline) + $7.35M potential earn-out.  \n  - **Net cash post-sale & debt repayment**: $16.49M (debt-free as of 9 July 2025).  \n\n- **US Business**:  \n  - **4Q revenue**: $10.1M (\u219334% pcp); **$4.8M revenue deferred to 1H FY26**.  \n  - **Pipeline**: US$125M (unweighted) for FY26.  \n  - **Strategic review ongoing** (potential sale).  \n\n- **FY25 Guidance Downgrade**:  \n  - **Revenue**: $88.0M (vs. $93\u201399M prior).  \n  - **EBITDA loss**: $6.5\u20137.3M (vs. $2.6\u20135.5M prior).  \n\n- **Cash Position**:  \n  - **Closing cash**: $12.55M (Appendix 4C).  \n\n#### **Key Forward-Looking Statements**  \n- **FY26 revenue growth target**: \u226515% YoY.  \n- **Cost reductions**: FY26 operating expenses \u219310% vs. FY25.  \n\n**No other material information identified.**",
  "usage": {
    "prompt_tokens": 5822,
    "completion_tokens": 440,
    "total_tokens": 6262,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T23:38:55.115858"
}